Novel Targeted Therapies for Renal Cell Carcinoma Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition
Saliby R, Saad E, Labaki C, Xu W, Braun D, Viswanathan S, Bakouny Z. Novel Targeted Therapies for Renal Cell Carcinoma Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition. Hematology/Oncology Clinics Of North America 2023, 37: 1015-1026. PMID: 37385938, DOI: 10.1016/j.hoc.2023.05.022.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsCarcinoma, Renal CellHumansKidney NeoplasmsTOR Serine-Threonine KinasesVascular Endothelial Growth Factor AConceptsRenal cell carcinomaTreatment of RCCTargeted therapyNovel Targeted TherapiesVHL/HIF pathwayVascular endothelial growth factorEndothelial growth factorCell carcinomaMetabolic targetingMTOR inhibitionMTOR pathwayGrowth factorTherapyPromising novelHIF pathwayTreatmentOxygen homeostasisEpigenomic reprogrammingRemarkable advancesPathwayCarcinomaCirculating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Saliby R, Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane M, Madsen K, Ficial M, Hirsch L, Wei X, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Lee G, Xu W, Van Allen E, McGregor B, Signoretti S, Choueiri T, McKay R, Braun D. Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma. Cancer Immunology Research 2023, 11: 1114-1124. PMID: 37279009, PMCID: PMC10526700, DOI: 10.1158/2326-6066.cir-22-0996.Peer-Reviewed Original ResearchMeSH KeywordsB7-H1 AntigenBevacizumabCarcinoma, Renal CellHumansKidney NeoplasmsVascular Endothelial Growth Factor AConceptsRenal cell carcinomaT cellsWorse PFSImmunotherapy responseCell carcinomaPeripheral immune cell populationsWorse progression-free survivalSarcomatoid renal cell carcinomaPhase II clinical trialImmunotherapy-based combinationsValue of tumourPoor-risk patientsProgression-free survivalImmune cell populationsVascular endothelial growth factorKidney cancer diagnosisEndothelial growth factorFuture biomarker studiesLack of responseInflammatory modulesExhausted CD8Variant histologyOverall survivalPD-L1Sarcomatoid differentiation